2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T5c7,Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in chemoimmunotherapy-treated patients remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates inconsistently with overall survival (OS), underscoring the importance of examining other surrogates. Progression of disease within 24 months (POD24), an established early endpoint, delineates functionally high-risk patients in other indolent lymphomas. This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. At median follow-up of 5.9 years, 5-year PFS and OS were 65% and 87%, respectively; 5-year PFS was similar between MYD88L265P (90%) and MYD88wild-type (WT) subcohorts (64% each, p=0.4). Among 89 patients with known CXCR4 status, the subcohort with CXCR4mutation (28%) had shorter PFS (median, 3.3 versus 8.8 years; HR 2.8, p=0.0036) and OS (HR 2.6, p=0.036) compared to CXCR4WT. POD24 occurred in 11.5% of patients who demonstrated inferior subsequent OS (5-year OS: 71% versus 86%; HR 3.1, p=0.005) and higher mortality (SMR 3.7), unlike the non-POD24 group, whose mortality was comparable to the matched general population (SMR 1.1). In conclusion, BR is effective, irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Non-POD24 patients represent a cohort with distinctly favorable outcome.31:T5d8,Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in chemoimmunotherapy-treated patients remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates inconsistently with overall survival (OS), underscoring the importance of examining other surrogates. Progression of disease within 24 months (POD24), an established early endpoint, delineates functionally high-risk patients in other indolent lymphomas. This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. At median follow-up of 5.9 years, 5-year PFS and OS were 65% and 87%, respectively; 5-year PFS was similar between MYD88L265P (90%) and MYD88wild-type (WT) subcohorts (64% each, p=0.4). Among 89 patients with known CXCR4 status, the subcohort with CXCR4mutation (28%) had shorter PFS (median, 3.3 versus 8.8 years; HR 2.8, p=0.0036) and OS (HR 2.6, p=0.036) compared to CXCR4WT. POD24 occurred in 11.5% of patients who demonstrated inferior subsequent OS (5-year OS: 71% versus 86%; HR 3.1, p=0.005) and higher mortality (SMR 3.7), unlike the non-POD24 group, whose mortality was comparable to the matched general population (SMR 1.1). In conclusion, BR is effective, irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Non-POD24 patients represent a cohort with distinctly favorable outcome.32:T7b0,High-grade B-cell lymphoma with "double-hit" MYC and BCL2 rearrangements (HGBCL-DH-BCL2) is associated with poor outcomes following standard chemoimmunotherapy, prompting dose-intensive regimen use. However, the benefit of intensification is unclear due to rarity precluding randomized trials, and selection bias in retrospective comparisons. In 2015, BC Cancer introduced a provincial guideline recommending dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) for fit patients aged ≤75 years with HGBCL-DH-BCL2 identified by routine cytogenetic testing. To assess this guideline's impact, we compared the outcomes of patients with de novo HGBCL-DH-BCL2 tumors of diffuse large B-cell lymphoma (DLBCL) morphology across 2 eras. The DA-EPOCH-R era (2015-2020) included patients diagnosed after guideline implementation. The historic era (2005-2010) included patients identified from a historic province-wide cohort of patients with DLBCL morphology tumors that underwent universal cytogenetic testing in a research setting, predominantly treated with standard chemoimmunotherapy. Two-year overall survival (OS) was significantly improved in the DA-EPOCH-R vs historic era (75% vs 47%, P = .008) in HGBCL-DH-BCL2, whereas OS remained unchanged in DLBCL, not otherwise specified (78% vs 76%, P = .17). Within HGBCL-DH-BCL2, tumors harboring immunoglobulin MYC partner loci (43%) and those expressing the dark-zone signature (77%) were associated with the most substantial survival improvements. In a contemporary cohort of HGBCL-DH-BCL2 histologically transformed from follicular lymphoma (FL) in the DA-EPOCH-R era, outcomes of patients who were chemoimmunotherapy-naïve were comparable to those with de novo disease, whereas patients treated with chemoimmunotherapy for FL prior to transformation had poor outcomes. These data support using DA-EPOCH-R in select patients with HGBCL-DH-BCL2 of DLBCL morphology.33:T836, Abstract High-grade B-cell lymphoma with "double-hit" MYC and BCL2 rearrangements (HGBCL-DH-BCL2) is associated with poor outcomes following standard chemoimmunotherapy, prompting dose-intensive regimen use. However, the benefit of intensification is unclear due to rarity precluding randomized trials, and selection bias in retrospective comparisons. In 2015, BC Cancer introduced a provincial guideline recommending dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) for fit patients aged ≤75 years with HGBCL-DH-BCL2 identified by routine cytogenetic testing. To assess this guideline’s impact, we compared the outcomes of patients with de novo HGBCL-DH-BCL2 tumors of diffuse large B-cell lymphoma (DLBCL) morphology across 2 eras. The DA-EPOCH-R era (2015-2020) included patients diagnosed after guideline implementation. The historic era (2005-2010) included patients identified from a historic province-wide cohort of patients with DLBCL morphology tumors that underwent universal cytogenetic testing in a research setting, predominantly treated with standard chemoimmunotherapy. Two-year overall survival (OS) was significantly improved in the DA-EPOCH-R vs historic era (75% vs 47%, P = .008) in HGBCL-DH-BCL2, whereas OS remained unchanged in DLBCL, not otherwise specified (78% vs 76%, P = .17). Within HGBCL-DH-BCL2, tumors harboring immunoglobulin MYC partner loci (43%) and those expressing the dark-zone signature (77%) were associated with the most substantial survival improvements. In a contemporary cohort of HGBCL-DH-BCL2 histologically transformed from follicular lymphoma (FL) in the DA-EPOCH-R era, outcomes of patients who were chemoimmunotherapy-naïve were comparable to those with de novo disease, whereas patients treated with chemoimmunotherapy for FL prior to transformation had poor outcomes. These data support using DA-EPOCH-R in select patients with HGBCL-DH-BCL2 of DLBCL morphology. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Chemoimmunotherapy: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Chemoimmunotherapy (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Chemoimmunotherapy\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Chemoimmunotherapy\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Chemoimmunotherapy\"}]}}"}}]],["$","$L2f",null,{"title":"Chemoimmunotherapy: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Chemoimmunotherapy — concise summaries and practical next steps.","papers":[{"doi":"10.1016/j.lungcan.2026.109609","pmid":"42715648","title":"Artificial Intelligence–Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer: An International Multicenter Cohort Study","journal_title":"Lung Cancer","journal_issn":"0169-5002","published_at":"2026-09-05T00:00:00.000Z","url":"https://doi.org/10.1016/j.lungcan.2026.109609","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-15T06:17:48.582Z","updated_at":"2026-09-15T06:17:48.582Z","tags":[{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"modality","value":"Artificial Intelligence Pathology","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"sample_size","value":"n=135","value_numeric":135},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"study_design","value":"Retrospective Multicenter Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"warning","value":"Study does not report outcomes by specific immunotherapy agent or histologic subtype (e.g., squamous vs. adenocarcinoma), which may limit subgroup applicability.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"warning","value":"The AI algorithm is described but not commercially named or publicly identified in the abstract, so reproducibility details are limited.","value_numeric":null},{"paper_doi":"10.1016/j.lungcan.2026.109609","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously—while performance metrics are strong, the retrospective design and modest sample size (n=135) mean prospective validation is still needed before routine clinical adoption.","value_numeric":null}],"summaries":{"what_studied":"An AI algorithm for scoring residual viable tumor (%RVT) was benchmarked against weighted expert consensus in 135 NSCLC patients treated with neoadjuvant chemoimmunotherapy across four international cohorts (internal + China, Germany, Spain) using 1,344 H&E slides.","key_result":"For major pathologic response (MPR) classification, the AI achieved pooled accuracy 91% (95% CI 85–95), sensitivity 90% (82–95), specificity 93% (81–99), and AUC ≥0.95 in all cohorts; discordant classifications occurred in 8.9% of cases, mostly from stromal underrepresentation and misclassification of non-neoplastic elements.","limitations":"- Retrospective design with modest total sample size (n=135) limits generalizability.\n- Discordant cases suggest the algorithm shares some failure modes with human pathologists (e.g., stromal and non-neoplastic element misclassification), not uniquely AI errors.\n- Performance on rarer histologic subtypes or highly heterogeneous tumors is not separately reported.","practice_takeaway":"This AI tool reliably classifies MPR from H&E slides across scanners and institutions, matching expert pathologist consensus—making it a candidate for standardizing pathologic response assessment in neoadjuvant NSCLC trials and clinical practice. Clinicians and pathologists should remain alert to edge cases involving dense stroma or non-neoplastic mimics where both AI and human assessment may diverge."}},{"doi":"10.1016/s2352-3026(26)00191-2","pmid":"42660130","title":"Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial","journal_title":"The Lancet Haematology","journal_issn":"2352-3026","published_at":"2026-08-28T00:00:00.000Z","url":"https://doi.org/10.1016/s2352-3026(26)00191-2","source_score":15,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-02T06:22:24.128Z","updated_at":"2026-09-02T06:22:24.128Z","tags":[{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"condition","value":"Double-Hit Lymphoma","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"condition","value":"High-Grade B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"generic","value":"doxorubicin","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"generic","value":"etoposide","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"generic","value":"prednisone","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"generic","value":"vincristine","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"modality","value":"BCL2 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"sample_size","value":"n=66","value_numeric":66},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"warning","value":"89% of participants were white, limiting generalizability to more diverse populations.","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"warning","value":"The age range (18–80) spans both adult and older_adult groups; median age was 65, suggesting a predominantly older adult population.","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00191-2","tag_type":"warning","value":"The trial was closed early due to excess mortality in the venetoclax arm; results are from an underpowered phase 2 cohort and should not be interpreted as definitive efficacy data.","value_numeric":null}],"summaries":{"what_studied":"Phase 2 RCT (ALLIANCE A051701) comparing DA-EPOCH-R alone vs. DA-EPOCH-R plus venetoclax (600 mg oral, days 1–5 per cycle) in 66 newly diagnosed double-hit lymphoma patients aged 18–80, with median follow-up of 34.7 months.","key_result":"Adding venetoclax did not improve progression-free survival (median 7.7 vs. 28.4 months; HR 1.13, 95% CI 0.53–2.37; p=0.75) and was associated with significantly worse 24-month overall survival (52% vs. 72%; HR 2.49, 95% CI 1.03–6.04; p=0.038), including 6 on-treatment deaths (17%) in the venetoclax arm vs. 1 (3%) in the control arm, prompting early trial closure.","limitations":"- Small phase 2 sample (n=66), limiting statistical power.\n- Open-label design introduces potential performance bias.\n- Predominantly white patient population (89%) limits generalizability.","practice_takeaway":"Do not add venetoclax to DA-EPOCH-R for newly diagnosed double-hit lymphoma — it increases mortality without improving disease control. DA-EPOCH-R alone provides a useful efficacy benchmark (28.4-month median PFS) for designing future trials."}},{"doi":"10.1111/bjh.70768","pmid":"42634099","title":"The diagnosis and management of primary mediastinal B‐cell lymphoma: A British Society for Haematology guideline","journal_title":"British Journal of Haematology","journal_issn":"0007-1048","published_at":"2026-08-23T00:00:00.000Z","url":"https://doi.org/10.1111/bjh.70768","source_score":13,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-28T06:25:25.917Z","updated_at":"2026-08-28T06:25:25.917Z","tags":[{"paper_doi":"10.1111/bjh.70768","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"condition","value":"Aggressive B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"condition","value":"Primary Mediastinal B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"modality","value":"CAR T-Cell Therapy","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"modality","value":"Consolidative Radiotherapy","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"modality","value":"Immune Checkpoint Inhibition","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"modality","value":"PET-CT Imaging","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"warning","value":"No specific patient population size or individual trial data are available from the abstract alone; sample_size tag omitted accordingly.","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"warning","value":"The full guideline text was not included in the provided source — only the BSH guideline development process document (a procedural appendix) was present. All clinical content extracted is based solely on the abstract. Specific recommendations, evidence grades, drug regimens, and supporting trial data could not be verified from the full text.","value_numeric":null},{"paper_doi":"10.1111/bjh.70768","tag_type":"warning","value":"The guideline covers a UK clinical context; applicability to other health systems may vary.","value_numeric":null}],"summaries":{"what_studied":"This is a British Society for Haematology (BSH) guideline on the diagnosis and management of Primary Mediastinal B-Cell Lymphoma (PMBCL), updating the 2019 BSH Good Practice Paper to reflect advances in imaging, radiotherapy, chemoimmunotherapy, CAR T-cell therapy, and immune checkpoint inhibition.","key_result":"Key recommendations include: (1) use of PET-adapted approaches to guide radiotherapy decisions after first-line chemoimmunotherapy; (2) omission of consolidative radiotherapy in patients achieving complete metabolic response (CMR); and (3) a framework for managing Deauville stage 4 (DS4) and DS5 PET-CT responses after chemoimmunotherapy.","limitations":"The full guideline text was not available in the provided source — only the BSH guideline development process document was included. Specific GRADE-graded recommendations, trial data, and patient numbers from the guideline itself could not be extracted.","practice_takeaway":"In PMBCL patients who achieve a complete metabolic response after dose-intensive chemoimmunotherapy, consolidative radiotherapy may be omitted. Clinicians should use PET-CT Deauville scoring to guide subsequent treatment decisions, including escalation with CAR T-cell therapy or checkpoint inhibition."}},{"doi":"10.1001/jamaoto.2026.2259","pmid":"42593779","title":"Pathologic Response After Neoadjuvant Chemoimmunotherapy in Head and Neck Squamous Cell Carcinoma","journal_title":"JAMA Otolaryngology–Head & Neck Surgery","journal_issn":"2168-6181","published_at":"2026-08-13T00:00:00.000Z","url":"https://doi.org/10.1001/jamaoto.2026.2259","source_score":37,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-17T13:33:04.181Z","updated_at":"2026-08-17T13:33:04.181Z","tags":[{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"condition","value":"Head and Neck Squamous Cell Carcinoma","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"modality","value":"Immunotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"modality","value":"Neoadjuvant Chemotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"sample_size","value":"n=86","value_numeric":86},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"warning","value":"Patients with locoregional recurrence were included alongside treatment-naive patients, which may introduce heterogeneity in the study population.","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously given this is a retrospective single-center study — prospective confirmation is explicitly called for by the authors.","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"warning","value":"The specific immunotherapy and chemotherapy agents used are not named in the abstract; brand/generic drug tags could not be assigned.","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2259","tag_type":"warning","value":"The upper bound of the adjusted OR confidence interval (274.7) is extremely wide, indicating low precision; results should be interpreted with caution.","value_numeric":null}],"summaries":{"what_studied":"This single-center retrospective cohort study compared pathologic response rates between neoadjuvant immunotherapy alone (NAI) and neoadjuvant chemoimmunotherapy (NACI) in 86 adults with resectable HNSCC of the aerodigestive tract, treated at a tertiary academic center from July 2024 to March 2026.","key_result":"Deep pathologic response (pCR or MPR) occurred in 39/58 NACI recipients (67%) vs. 1/28 NAI recipients (3.6%); propensity score-adjusted OR for pCR or MPR with NACI was 29.1 (95% CI, 6.7–274.7). Overall, 25 patients (29%) achieved pCR and 15 (17%) achieved MPR. Treatment was generally well tolerated with few adverse event-related surgical delays.","limitations":"- Single-center retrospective design with a small sample (n=86) limits generalizability and statistical precision.\n- Wide confidence intervals (especially in the adjusted OR: 6.7–274.7) reflect limited statistical power and residual confounding despite propensity score adjustment.\n- No survival outcomes reported; pathologic response is a surrogate endpoint whose link to OS in this context remains unconfirmed.","practice_takeaway":"NACI produced dramatically higher deep pathologic response rates than NAI alone in resectable HNSCC (67% vs. 3.6%), without apparent excess surgical delays. Clinicians should consider combination chemoimmunotherapy in the neoadjuvant setting, while awaiting prospective trial data on survival benefit."}},{"doi":"10.1182/blood.2026033839","pmid":"42622258","title":"Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-08-11T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2026033839","source_score":19,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-26T06:20:06.379Z","updated_at":"2026-08-26T06:20:06.379Z","tags":[{"paper_doi":"10.1182/blood.2026033839","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"brand","value":"Epkinly","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"doxorubicin","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"epcoritamab","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"prednisone","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"vincristine","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"sample_size","value":"n=47","value_numeric":47},{"paper_doi":"10.1182/blood.2026033839","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"study_design","value":"Phase 1b/2 Single-Arm Trial","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"warning","value":"No direct comparator arm was included; the 2-year PFS/OS figures cannot be formally compared to historical R-CHOP data without adjustment for patient selection.","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"warning","value":"The brand name 'Epkinly' is used for epcoritamab; confirm regulatory approval status in your region for the frontline LBCL indication, as this trial is investigational.","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"warning","value":"The phase 3 confirmatory trial (NCT04663347 or successor) is described as 'ongoing' — clinicians should check for updated results before adopting this regimen.","value_numeric":null}],"summaries":{"what_studied":"Phase 1b/2 single-arm study (EPCORE NHL-2, Arm 1) evaluating epcoritamab added to R-CHOP (6 cycles) for 1 year total in 47 adults with newly diagnosed CD20+ LBCL and high-risk IPI scores of 3–5.","key_result":"ORR was 98% and CR rate was 85%; at median follow-up of 44.2 months, median DOCR, PFS, and OS were not reached; estimated 2-year PFS was 80% and 2-year OS was 87%. MRD negativity was achieved in 100% of evaluable patients. CRS occurred in 60% of patients but was predominantly grade 1–2 and all events resolved.","limitations":"Single-arm design with no comparator limits conclusions about benefit over R-CHOP alone; small sample size (n=47) reduces precision; investigator-assessed endpoints introduce potential bias.","practice_takeaway":"For high-risk newly diagnosed LBCL (IPI 3–5), epcoritamab plus R-CHOP showed durable responses in this early-phase study — but wait for the ongoing phase 3 trial before changing frontline practice. CRS was common yet manageable, so step-up dosing protocols and monitoring should be in place."}},{"doi":"10.1002/hem3.70443","pmid":"42553584","title":"First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma","journal_title":"HemaSphere","journal_issn":"2572-9241","published_at":"2026-08-04T00:00:00.000Z","url":"https://doi.org/10.1002/hem3.70443","source_score":17,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-12T13:26:11.758Z","updated_at":"2026-08-12T13:26:11.758Z","tags":[{"paper_doi":"10.1002/hem3.70443","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"brand","value":"Epkinly","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"condition","value":"Follicular Lymphoma","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"generic","value":"bendamustine","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"generic","value":"epcoritamab","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"sample_size","value":"n=25","value_numeric":25},{"paper_doi":"10.1002/hem3.70443","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"study_design","value":"Phase 1b/2 Single-Arm Trial","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"warning","value":"Brand name 'Epkinly' added based on known epcoritamab branding; the paper itself does not use this proprietary name.","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"warning","value":"One case of biopsy-confirmed PML was reported; this rare but serious adverse event may be underrecognized in the broader FL treatment community.","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"warning","value":"Sample size is very small (n=25); subgroup analyses (e.g., bulky disease n=7, bone marrow involvement n=12) should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"warning","value":"Study design is labeled Phase 1b/2 single-arm; level of evidence assigned as 3 (non-randomized controlled study) but may be considered level 4 given the lack of a comparator arm.","value_numeric":null},{"paper_doi":"10.1002/hem3.70443","tag_type":"warning","value":"The high COVID-19 infection rate (84%) is likely a pandemic-era confounder and may not reflect current real-world risk.","value_numeric":null}],"summaries":{"what_studied":"This phase 1b/2 single-arm trial (EPCORE NHL-2, arm 3) evaluated epcoritamab (subcutaneous CD3×CD20 bispecific antibody) combined with bendamustine plus rituximab (BR) for 6 cycles, followed by epcoritamab monotherapy for up to 2 years, in 25 previously untreated follicular lymphoma (FL) patients; median follow-up was 41.3 months.","key_result":"Best ORR and CR rate were both 96% (24/25 patients); median time to CR was 1.5 months. At 3 years, 87% of responders maintained CR, 3-year PFS was 83%, and 3-year OS was 96%. Only 3 patients (12%) had progression within 24 months (POD24). All CRS events were low grade (grade 1–2); no ICANS or clinical TLS occurred. Infections affected 92% of patients, with COVID-19 most common (84%); 1 fatal COVID-19 case and 1 biopsy-confirmed PML case were reported.","limitations":"- Single-arm, non-randomized design with only 25 patients limits comparative conclusions and generalizability, especially for subgroup analyses.\n- High COVID-19 infection rate (84%) confounds the safety interpretation, as the trial ran during the pandemic.\n- Immunophenotyping data were not collected beyond cycle 7, limiting assessment of T-cell recovery during epcoritamab monotherapy.","practice_takeaway":"In treatment-naïve FL patients with high disease burden, adding epcoritamab to BR yields deep, durable CRs sustained beyond 3 years, but the high infection burden—particularly COVID-19 and opportunistic infections—warrants careful patient selection and proactive infection prophylaxis. Confirmation in randomized trials is still needed before this replaces standard BR."}},{"doi":"10.1111/bjh.70730","pmid":"42500826","title":"Comparison of outcomes after\n DA\n ‐\n EPOCH\n ‐R or\n GMALL\n high‐intensity therapy for front‐line treatment of Burkitt lymphoma: A retrospective cohort","journal_title":"British Journal of Haematology","journal_issn":"0007-1048","published_at":"2026-07-25T00:00:00.000Z","url":"https://doi.org/10.1111/bjh.70730","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:08.016Z","updated_at":"2026-07-31T13:37:08.016Z","tags":[{"paper_doi":"10.1111/bjh.70730","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"brand","value":"DA-EPOCH-R","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"condition","value":"Burkitt Lymphoma","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"generic","value":"etoposide/prednisone/vincristine/cyclophosphamide/doxorubicin/rituximab","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"warning","value":"DA-EPOCH-R is listed as a brand-style acronym rather than a true proprietary brand name; tagged for clarity but it represents a regimen, not a single drug.","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"warning","value":"GMALL 'high-intensity therapy' may encompass multiple protocol variants — specific regimens used are not detailed in the abstract.","value_numeric":null},{"paper_doi":"10.1111/bjh.70730","tag_type":"warning","value":"Sample size and follow-up duration are not reported in the abstract; absolute outcome numbers are unavailable.","value_numeric":null}],"summaries":{"what_studied":"Retrospective cohort comparing front-line DA-EPOCH-R versus GMALL-based high-intensity chemotherapy regimens in adult Burkitt lymphoma patients, evaluating survival and relapse outcomes.","key_result":"DA-EPOCH-R showed no signal of inferior survival or relapse risk compared with GMALL-based high-intensity therapy; outcomes were primarily driven by age, advanced stage, and the Burkitt Lymphoma International Prognostic Index (BL-IPI).","limitations":"Retrospective design limits causal inference; potential selection bias in regimen choice; sample size and follow-up duration not specified in the abstract.","practice_takeaway":"For adult Burkitt lymphoma, DA-EPOCH-R appears to be a reasonable front-line alternative to intensive GMALL-based regimens without worse survival outcomes. Prognostic stratification by age, stage, and BL-IPI should guide risk assessment regardless of regimen chosen."}},{"doi":"10.1182/bloodadvances.2026020988","pmid":"42341324","title":"Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2026-06-24T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2026020988","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-19T06:28:57.970Z","updated_at":"2026-08-19T06:28:57.970Z","tags":[{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"condition","value":"Diffuse Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"condition","value":"High Grade B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"condition","value":"Primary Mediastinal B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"modality","value":"Circulating Tumor DNA (ctDNA) Testing","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"modality","value":"PET Imaging","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"sample_size","value":"n=367","value_numeric":367},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"study_design","value":"Meta-Analysis","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"warning","value":"Cell-of-origin (GCB vs. non-GCB) data were only available for the Roschewski cohort, limiting subgroup generalizability.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"warning","value":"R-CHOP regimen data were only partially reported across cohorts (missing for Roschewski cohort), so treatment homogeneity across the meta-analysis cannot be fully confirmed.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"warning","value":"The full text available contains only supplementary tables and a CONSORT diagram; primary survival outcome data (HRs, OS/PFS curves, p-values) are not present in the provided source and could not be summarized.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"warning","value":"The meta-analysis sample size of 367 reflects eligible patients across three cohorts; total enrolled was 422, but 55 were excluded from the meta-analysis for unstated reasons per the CONSORT diagram reference.","value_numeric":null}],"summaries":{"what_studied":"This meta-analysis pooled three cohorts (Roschewski, Wang, Krupka cohort 2; total N=367 in meta-analysis) to evaluate the prognostic value of combined phased-variant ctDNA (MRD) testing and end-of-treatment PET response in large B-cell lymphoma patients.","key_result":"Across cohorts, MRD−/PET− was the most common end-of-treatment category (66–72% of patients); MRD+/PET+ occurred in 10–12%, and discordant groups (MRD−/PET+ or MRD+/PET−) each comprised ~7–13% of patients. Specific survival outcome data (HRs, OS/PFS rates) are not fully reported in the available text.","limitations":"Only two ctDNA testing platforms were used (Foresight Diagnostics and University of Cambridge), limiting generalizability; staging and cell-of-origin data were incomplete across cohorts; median follow-up was relatively short in one cohort (24.5 months).","practice_takeaway":"Combined ctDNA MRD and PET assessment at end of treatment identifies a meaningful subset (~10–13%) of large B-cell lymphoma patients who are MRD+/PET+ and may warrant intensified follow-up or treatment strategies. Discordant MRD/PET results (each ~7–13%) highlight that neither test alone captures full residual disease burden."}},{"doi":"10.1016/j.athoracsur.2026.05.037","pmid":"42264017","title":"STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY","journal_title":"The Annals of Thoracic Surgery","journal_issn":"0003-4975","published_at":"2026-06-09T00:00:00.000Z","url":"https://doi.org/10.1016/j.athoracsur.2026.05.037","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-21T13:29:47.820Z","updated_at":"2026-06-21T13:29:47.820Z","tags":[{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"condition","value":"Stage II Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"modality","value":"Neoadjuvant Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"modality","value":"Surgery","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"sample_size","value":"n=7617","value_numeric":7617},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"study_design","value":"Individual Patient Data Meta-Analysis","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"warning","value":"IPD was reconstructed using the IPDfromKM method rather than obtained directly from trial sponsors, which may introduce statistical reconstruction error.","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"warning","value":"The divergence in OS benefit between TNM 8th and 9th edition comparisons is a key ambiguity — the study does not clearly adjudicate which edition is more appropriate for current practice.","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously: the authors themselves call for stratification tools and do not recommend an immediate practice shift.","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.05.037","tag_type":"warning","value":"The total sample size tag reflects the largest surgical comparator group (9th-edition TNM database, n=7,342) plus chemoimmunotherapy arm (n=275); the true combined analytic N varies by comparison. Exact total N is not explicitly stated for all analyses.","value_numeric":null}],"summaries":{"what_studied":"This IPD meta-analysis compared overall survival in stage-II NSCLC patients (AJCC TNM 8th ed.) receiving neoadjuvant chemoimmunotherapy (n=275, from phase-3 RCTs) versus upfront surgery (n=6,864–7,342, from pathological TNM 8th/9th-edition databases). Secondary comparisons evaluated neoadjuvant chemoimmunotherapy vs. chemotherapy alone for pathologic response, event-free survival, and surgical outcomes.","key_result":"Chemoimmunotherapy improved OS vs. upfront surgery per the 8th-edition TNM database (HR=0.68, 95%CI 0.53–0.87, p=0.002), but not per the 9th-edition (HR=0.82, 95%CI 0.64–1.1, p=0.10). Vs. chemotherapy alone, chemoimmunotherapy yielded higher pCR (RR=6.19), major pathologic response (RR=3.08), better event-free survival (HR=0.66, p<0.001), and better OS (HR=0.68, p=0.01), with no difference in surgical complication rates.","limitations":"- The chemoimmunotherapy arm is small (n=275) and extracted via the IPDfromKM method rather than directly from individual patient records, introducing reconstruction error.\n- Comparison vs. upfront surgery relied on historical TNM registry data, not a randomized control group, with potential for selection bias.\n- Results diverge depending on which TNM edition (8th vs. 9th) is used as the benchmark, limiting definitive conclusions.","practice_takeaway":"For stage-II NSCLC, neoadjuvant chemoimmunotherapy offers better pathologic responses and event-free survival than chemotherapy alone, with no added surgical risk — but its OS benefit over upfront surgery remains uncertain and depends on staging classification. Clinicians should await better patient-selection tools before broadly shifting away from upfront surgery in this stage."}},{"doi":"10.1001/jamaoncol.2026.1548","pmid":"42240993","title":"PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression","journal_title":"JAMA Oncology","journal_issn":"2374-2437","published_at":"2026-06-04T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13237700/","source_score":35,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:23:44.066Z","updated_at":"2026-06-10T14:23:44.066Z","tags":[{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"modality","value":"PD-1/PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"modality","value":"Platinum-Based Chemotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"sample_size","value":"n=5546","value_numeric":5546},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"study_design","value":"Meta-Analysis of Randomized Controlled Trials","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"warning","value":"No prospective head-to-head RCT directly comparing chemoimmunotherapy to PD-(L)1 monotherapy exists; findings rely on indirect comparisons across heterogeneous trials.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"warning","value":"Specific agents (e.g., pembrolizumab, atezolizumab, nivolumab) are not broken out by name in the abstract; brand/generic tags are omitted to avoid misattribution.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously — the authors themselves call for confirmatory prospective trials.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.1548","tag_type":"warning","value":"Toxicity data and quality-of-life outcomes are not reported in the abstract, which limits direct clinical translation.","value_numeric":null}],"summaries":{"what_studied":"This meta-analysis of 24 phase 3 RCTs compared PD-(L)1 inhibitor monotherapy vs chemoimmunotherapy as first-line treatment in 5,546 treatment-naive patients with advanced NSCLC and PD-L1 expression ≥50%, using OS and PFS as outcomes.","key_result":"Chemoimmunotherapy showed superior OS (median 29.2 vs 19.8 months; HR 0.74 [95% CI 0.66–0.82]) and PFS (median 11.3 vs 6.8 months; HR 0.67 [95% CI 0.60–0.75]) compared to PD-(L)1 inhibitor monotherapy; both strategies beat chemotherapy alone, but chemoimmunotherapy had a larger benefit.","limitations":"- Indirect comparison across trials (no head-to-head RCT); patient populations, chemotherapy backbones, and specific agents varied across the 24 included studies.\n- Reconstructed individual patient data from Kaplan-Meier curves introduce estimation error.\n- Subgroup analyses (e.g., by histology, EGFR/ALK status, or smoking status) that could identify who truly benefits from monotherapy are not reported in the abstract.","practice_takeaway":"For fit patients with advanced NSCLC and PD-L1 ≥50%, adding chemotherapy to immunotherapy appears to meaningfully extend both OS and PFS compared to immunotherapy alone — clinicians should weigh this survival gain against the added toxicity burden of chemoimmunotherapy.\n\nProspective head-to-head trials are still needed before this can be considered definitive practice-changing evidence."}},{"doi":"10.1016/j.ctrv.2026.103144","pmid":"42114275","title":"KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians","journal_title":"Cancer Treatment Reviews","journal_issn":"0305-7372","published_at":"2026-05-06T00:00:00.000Z","url":"https://doi.org/10.1016/j.ctrv.2026.103144","source_score":20,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-15T13:23:03.752Z","updated_at":"2026-05-15T13:23:03.752Z","tags":[{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"brand","value":"Krazati","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"brand","value":"Lumakras","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"condition","value":"KRAS G12C-Mutant NSCLC","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"condition","value":"Non-Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"generic","value":"adagrasib","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"generic","value":"sotorasib","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"modality","value":"Immunotherapy","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"modality","value":"KRAS Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"warning","value":"No sample size tag applied as this is a review article with no primary patient cohort.","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"warning","value":"Sex distribution of included populations is not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"warning","value":"Some 'next-generation' and pan-RAS inhibitors discussed may be investigational and not yet approved; clinicians should confirm regulatory status.","value_numeric":null},{"paper_doi":"10.1016/j.ctrv.2026.103144","tag_type":"warning","value":"This is a narrative review published in 2026; some referenced trials may be ongoing or recently reported — verify current phase III trial status before applying to clinical decisions.","value_numeric":null}],"summaries":{"what_studied":"A comprehensive clinical review of KRAS G12C-mutant NSCLC (~15% of NSCLC cases), covering biology, efficacy, safety, and practical use of KRAS inhibitors across treatment lines, including combinations with immunotherapy and chemoimmunotherapy.","key_result":"Sotorasib and adagrasib are standard second-line options but offer only modest PFS benefit over chemotherapy. First-line KRAS inhibitor + immunotherapy combinations look promising in high PD-L1 tumors; adding KRAS inhibitors to chemoimmunotherapy may provide broader benefit regardless of PD-L1 level. Next-generation and pan-RAS inhibitors show early promise, but confirmatory phase III data are pending.","limitations":"- No original trial data presented; conclusions are based on synthesized existing evidence.\n- Phase III confirmatory trials for next-generation and combination regimens are still pending.\n- Key questions on optimal patient selection, co-mutation impact, CNS activity, and dose optimization remain unanswered.","practice_takeaway":"Use sotorasib or adagrasib as standard second-line therapy for KRAS G12C-mutant NSCLC, but counsel patients that benefit over chemotherapy is modest. In the first-line setting, watch for emerging data on KRAS inhibitor + chemoimmunotherapy combinations, which may benefit patients across all PD-L1 expression levels."}},{"doi":"10.1182/blood.2025030630","pmid":"41770817","title":"Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-03-02T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025030630","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-16T13:54:36.620Z","updated_at":"2026-06-16T13:54:36.620Z","tags":[{"paper_doi":"10.1182/blood.2025030630","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"brand","value":"Gazyva","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"brand","value":"Venclexta","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"condition","value":"Chronic Lymphocytic Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"bendamustine","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"fludarabine","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"obinutuzumab","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"generic","value":"venetoclax","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"modality","value":"Anti-CD20 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"modality","value":"BCL-2 Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"sample_size","value":"n=166","value_numeric":166},{"paper_doi":"10.1182/blood.2025030630","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"warning","value":"PFS data were immature at the time of this primary analysis; long-term survival outcomes remain unknown.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"warning","value":"The comparator arm used two different regimens (FCR or BR), chosen at investigator discretion, which may confound cross-arm comparisons.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"warning","value":"The impact_flag 'confirms_prior' was assigned because the authors explicitly state these results confirm and extend findings from the GAIA-CLL13 trial.","value_numeric":null},{"paper_doi":"10.1182/blood.2025030630","tag_type":"warning","value":"The trial enrolled only fit patients (CIRS ≤6, CrCl ≥70 mL/min) without del(17p)/TP53 mutations; results should not be extrapolated to unfit or high-risk CLL populations.","value_numeric":null}],"summaries":{"what_studied":"Phase 3 RCT (CRISTALLO, NCT04285567) comparing fixed-duration venetoclax-obinutuzumab (VenO, n=80) vs FCR/BR (n=86) as first-line therapy in fit CLL patients (CIRS ≤6, CrCl ≥70 mL/min, no del(17p)/TP53 mutations); primary endpoint was uMRD (<10⁻⁴) in peripheral blood at month 15 by NGS.","key_result":"VenO met the primary endpoint: 81.3% achieved uMRD (<10⁻⁴) in PB at month 15 vs 54.7% with FCR/BR (P=.0004). Deeper responses were also superior: 65.0% vs 25.6% achieved uMRD (<10⁻⁶) in PB at month 15. BM uMRD (<10⁻⁴) at EOT was 70.0% (VenO) vs 38.4% (FCR/BR). Fewer patients progressed or died with VenO (7 vs 13); PFS analysis was not yet mature.","limitations":"- Follow-up was too short for a meaningful PFS comparison at the first planned interim analysis.\n- The trial excluded del(17p)/TP53-mutated patients, limiting generalizability to higher-risk CLL.\n- Patients in the FCR/BR arm received two different regimens (FCR or BR), introducing heterogeneity in the comparator.","practice_takeaway":"For fit, treatment-naive CLL patients without del(17p)/TP53 mutations, fixed-duration VenO achieves significantly deeper MRD responses than FCR or BR—including at the stringent <10⁻⁶ threshold—with a manageable and predictable safety profile. Obinutuzumab debulking eliminated high TLS risk before venetoclax initiation, and no clinical TLS occurred, supporting this sequencing strategy."}},{"doi":"10.1001/jamaoncol.2026.0042","pmid":"41746629","title":"Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy","journal_title":"JAMA Oncology","journal_issn":"2374-2437","published_at":"2026-02-26T00:00:00.000Z","url":"https://doi.org/10.1001/jamaoncol.2026.0042","source_score":113,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-15T13:23:01.590Z","updated_at":"2026-05-15T13:23:01.590Z","tags":[{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"brand","value":"Rituxan","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"condition","value":"Follicular Lymphoma","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"generic","value":"doxorubicin","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"generic","value":"prednisone","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"generic","value":"vincristine","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"modality","value":"Radioimmunotherapy","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"sample_size","value":"n=531","value_numeric":531},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"warning","value":"CHOP-RIT involves radioimmunotherapy (e.g., ibritumomab tiuxetan), which is not explicitly named in the paper — the specific radioimmunotherapy agent used in S0016 was ibritumomab tiuxetan (Zevalin), but this is not confirmed in the provided text.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"warning","value":"Enrollment occurred from 2001–2008; treatment landscape for FL has changed substantially since then (e.g., obinutuzumab, lenalidomide combinations), which may limit generalizability of the CHOP-RIT arm findings.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0042","tag_type":"warning","value":"The level of evidence is tagged as '2' (RCT with long-term follow-up), but the cure modeling component is a secondary/exploratory analysis, which carries lower evidentiary weight than the primary trial outcomes.","value_numeric":null}],"summaries":{"what_studied":"The SWOG S0016 trial compared R-CHOP vs. CHOP followed by radioimmunotherapy (CHOP-RIT) in 531 adults with untreated advanced-stage follicular lymphoma (FL), with 15-year follow-up (median 15.5 years) and cure modeling using background mortality rates.","key_result":"15-year OS was 70% (no difference between arms); 15-year PFS was 40% overall, but CHOP-RIT was superior to R-CHOP (47% vs. 34%; P = .004). Cure modeling estimated 42% of patients were cured, with relapse rates falling from 6.8% (years 0–5) to 0.6% (years 15–20). Highest cure rates were seen in patients with low FLIPI scores and normal β2-microglobulin.","limitations":"- Secondary/exploratory analysis of a trial not originally powered for cure modeling.\n- Enrollment ended in 2008; CHOP-RIT regimen (radioimmunotherapy) is rarely used in current practice, limiting direct applicability.\n- Long follow-up introduces informative censoring and competing mortality risks.","practice_takeaway":"A meaningful subset (~42%) of advanced-stage FL patients treated with CHOP-based chemoimmunotherapy may achieve long-term cure — clinicians should incorporate this into initial patient counseling. Low FLIPI score and normal β2-microglobulin identify patients most likely to be in the cured fraction."}},{"doi":"10.1182/bloodadvances.2025017751","pmid":"41499755","title":"POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2026-01-07T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2025017751","source_score":13,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-11","doi":"10.1182/bloodadvances.2025017751","days":"7","issn":"2473-9529","rank":"10","field":"Clinical Medicine","score":"13","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1182/bloodadvances.2025017751","title":"POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.","journal":"Blood advances","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"41499755","conclusions":"","publication_date":"2026-01-07T00:00:00"},"crossref":{"DOI":"10.1182/bloodadvances.2025017751","URL":"https://doi.org/10.1182/bloodadvances.2025017751","ISSN":["2473-9529","2473-9537"],"link":[{"URL":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025017751/2497248/bloodadvances.2025017751.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025017751/2497248/bloodadvances.2025017751.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia"],"author":[{"given":"Saurabh","family":"Zanwar","sequence":"first","affiliation":[{"name":"Mayo Clinic, rochester, Minnesota, United States"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Shirley","family":"D'Sa","sequence":"additional","affiliation":[{"name":"UCLH Centre for Waldenströms Macroglobulinaemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[{"name":"Pitié-Salpêtrière, paris, France"}]},{"given":"Dirk R.","family":"Larson","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Colin L.","family":"Colby","sequence":"additional","affiliation":[{"name":"Mayo Clinic, rochester, Minnesota, United States"}]},{"given":"Eric","family":"Durot","sequence":"additional","affiliation":[{"name":"Hôpital Robert Debré CHU de Reims, Reims cedex, France"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}]},{"given":"Encarl","family":"Uppal","sequence":"additional","affiliation":[{"name":"UCLH Centre for Waldenströms Macroglobulinaemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}]},{"given":"Oliver","family":"Tomkins","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Tryst, London, United Kingdom"}]},{"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[{"name":"CHU Amiens Picardie, Amiens, France"}]},{"given":"Patrizia","family":"Mondello","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Lydia","family":"Montes","sequence":"additional","affiliation":[{"name":"CHU Amiens, Amiens, France"}]},{"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida, United States"}]},{"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts, United States"}]},{"given":"Olabisi","family":"Ogunbiyi","sequence":"additional","affiliation":[{"name":"UCLH Center for Waldenstroms, University College London Hospitals, London, United Kingdom, United Kingdom"}]},{"given":"Pascalle","family":"Cornillet-Lefebvre","sequence":"additional","affiliation":[{"name":"Hopital Robert debré, Reims, France"}]},{"given":"S Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Anne","family":"Quinquenel","sequence":"additional","affiliation":[{"name":"Hopital Robert Debré, CHU Reims, Reims, France"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, Arizona, United States"}]},{"given":"Morie A","family":"Gertz","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Shaji K","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, United States"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts, United States"}]},{"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, United States"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN, Rochester, Minnesota, United States"}]}],"issued":{"date-parts":[[2026,1,7]]},"member":"234","prefix":"10.1182","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T21:21:53Z","timestamp":1767820913000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T23:30:11Z","timestamp":1767828611954,"date-parts":[[2026,1,7]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc-nd/4.0/","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025017751/565887/POD24-is-a-Novel-Determinant-of-Prognosis-in"}},"subtitle":[],"deposited":{"date-time":"2026-01-07T21:21:53Z","timestamp":1767820913000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"American Society of Hematology","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1182/blood.2019cm0000","article-number":"bloodadvances.2025017751","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Blood Advances"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1182/bloodadvances.2025017751","is_oa":true,"title":"POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-07","best_oa_location":{"url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025017751/2497248/bloodadvances.2025017751.pdf","pmh_id":null,"url_for_pdf":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025017751/2497248/bloodadvances.2025017751.pdf","url_for_landing_page":"https://doi.org/10.1182/bloodadvances.2025017751"}}},"created_at":"2026-01-15T20:51:27.064Z","updated_at":"2026-01-16T11:56:46.634Z","tags":[{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"brand","value":"Rituxan","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"brand","value":"Treanda","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"condition","value":"Waldenström Macroglobulinemia","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"generic","value":"bendamustine","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"sample_size","value":"n=253","value_numeric":253},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"warning","value":"Abstract text appears internally inconsistent for 5‑year PFS by MYD88 (reports both “similar” and discordant percentages).","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017751","tag_type":"warning","value":"Study design not explicitly described; treated as a cohort study for classification.","value_numeric":null}],"summaries":{"what_studied":"An international cohort of 253 patients with Waldenström macroglobulinemia received frontline fixed‑duration bendamustine‑rituximab, with PFS, OS, and the prognostic value of MYD88, CXCR4, and POD24 evaluated at a median follow‑up of 5.9 years.","key_result":"At 5 years, PFS was 65% and OS 87%; PFS did not differ by MYD88 status (p=0.4). In 89 patients with CXCR4 data, mutations (28%) predicted shorter PFS (median 3.3 vs 8.8 years; HR 2.8; p=0.0036) and worse OS (HR 2.6; p=0.036), and POD24 (11.5%) identified worse subsequent OS (5‑year 71% vs 86%; HR 3.1; p=0.005) with higher mortality (SMR 3.7 vs 1.1).","limitations":"CXCR4 status was available in only 89 of 253 patients, limiting precision and generalizability of mutation analyses. Findings are confined to a single regimen (fixed‑duration bendamustine‑rituximab), and the study design was not explicitly stated.","practice_takeaway":"In WM treated with fixed‑duration bendamustine‑rituximab, MYD88 status did not affect PFS, while CXCR4 mutations and POD24 flagged patients with worse outcomes. Non‑POD24 patients had mortality comparable to the general population."}},{"doi":"10.1182/bloodadvances.2025017282","pmid":"41071951","title":"Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with\n MYC\n /\n BCL2\n rearrangements, DLBCL morphology","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2025-10-10T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2025017282","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-16","doi":"10.1182/bloodadvances.2025017282","days":"7","issn":"2473-9529","rank":"10","field":"Clinical Medicine","score":"11","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1182/bloodadvances.2025017282","title":"Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology.","journal":"Blood advances","methods":"","results":"","abstract":"$32","keywords":[],"pubmed_id":"41071951","conclusions":"","publication_date":"2025-10-10T00:00:00"},"crossref":{"DOI":"10.1182/bloodadvances.2025017282","URL":"https://doi.org/10.1182/bloodadvances.2025017282","ISSN":["2473-9529","2473-9537"],"link":[{"URL":"https://ashpublications.org/bloodadvances/article-pdf/10/2/320/2497910/blooda_adv-2025-017282-main.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://ashpublications.org/bloodadvances/article-pdf/10/2/320/2497910/blooda_adv-2025-017282-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"320-333","type":"journal-article","issue":"2","score":1,"title":["Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with\n MYC\n /\n BCL2\n rearrangements, DLBCL morphology"],"author":[{"given":"Waleed","family":"Alduaij","sequence":"first","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Jean-Nicolas","family":"Champagne","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"3Hematology and Medical Oncology, Hôpital du Sacre-Coeur de Montréal, Montreal, QC, Canada"}]},{"given":"Brett","family":"Collinge","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Susana","family":"Ben-Neriah","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}]},{"given":"Aixiang","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Laura K.","family":"Hilton","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}]},{"given":"Merrill","family":"Boyle","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}]},{"given":"Barbara","family":"Meissner","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}]},{"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Pedro","family":"Farinha","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Jeffrey W.","family":"Craig","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"5Department of Pathology, University of Virginia Health System, Charlottesville, VA"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"6Department of Blood and Marrow Transplant and Cellular Therapy, Moffitt Cancer Center, Tampa, FL"}]},{"given":"Andrew J.","family":"Mungall","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"7Canada’s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada"}]},{"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}]}],"issued":{"date-parts":[[2026,1,27]]},"member":"234","prefix":"10.1182","source":"Crossref","volume":"10","created":{"date-time":"2025-10-10T19:09:56Z","timestamp":1760123396000,"date-parts":[[2025,10,10]]},"indexed":{"date-time":"2026-01-15T02:47:39Z","timestamp":1768445259477,"date-parts":[[2026,1,15]]},"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://ashpublications.org/bloodadvances/article/10/2/320/547660/Population-wide-introduction-of-dose-adjusted"}},"subtitle":[],"deposited":{"date-time":"2026-01-14T16:21:59Z","timestamp":1768407719000,"date-parts":[[2026,1,14]]},"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"published":{"date-parts":[[2026,1,27]]},"publisher":"American Society of Hematology","reference":[{"DOI":"10.1056/NEJM198805263182106","key":"2026011411214708100_bib1","year":"1988","issue":"21","author":"De Jong","volume":"318","first-page":"1373","unstructured":null,"article-title":"Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41375-022-01620-2","key":"2026011411214708100_bib2","year":"2022","issue":"7","author":"Alaggio","volume":"36","first-page":"1720","unstructured":null,"article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2022015851","key":"2026011411214708100_bib3","year":"2022","issue":"11","author":"Campo","volume":"140","first-page":"1229","unstructured":null,"article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41375-019-0691-6","key":"2026011411214708100_bib4","year":"2020","issue":"5","author":"Cucco","volume":"34","first-page":"1329","unstructured":null,"article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026011411214708100_bib5","year":"2021","issue":"S2","author":"Collinge","volume":"39","first-page":"111","unstructured":null,"article-title":"The mutational landscape of double/triple-hit high-grade B-cell lymphoma with BCL2 rearrangement- (DH/TH-BCL2) – an LLMPP project","journal-title":"Hematological Oncol","doi-asserted-by":null},{"DOI":"10.1016/j.ccell.2020.03.015","key":"2026011411214708100_bib6","year":"2020","issue":"4","author":"Wright","volume":"37","first-page":"551","unstructured":null,"article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","journal-title":"Cancer Cell","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.18.01583","key":"2026011411214708100_bib7","year":"2019","issue":"3","author":"Ennishi","volume":"37","first-page":"190","unstructured":null,"article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026011411214708100_bib8","year":"2023","issue":"20","author":"Alduaij","volume":"141","first-page":"2493","unstructured":null,"article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","journal-title":"Blood","doi-asserted-by":null},{"DOI":"10.1200/JCO.18.01314","key":"2026011411214708100_bib9","year":"2019","issue":"3","author":"Sha","volume":"37","first-page":"202","unstructured":null,"article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2015-06-649905","key":"2026011411214708100_bib10","year":"2015","issue":"18","author":"Kridel","volume":"126","first-page":"2118","unstructured":null,"article-title":"Cell of origin of transformed follicular lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2019002600","key":"2026011411214708100_bib11","year":"2019","issue":"18","author":"Hilton","volume":"134","first-page":"1528","unstructured":null,"article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024024251","key":"2026011411214708100_bib12","year":"2024","issue":"5","author":"Hilton","volume":"144","first-page":"525","unstructured":null,"article-title":"Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2009-03-212191","key":"2026011411214708100_bib13","year":"2009","issue":"11","author":"Johnson","volume":"114","first-page":"2273","unstructured":null,"article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.3324/haematol.2018.190157","key":"2026011411214708100_bib14","year":"2018","issue":"11","author":"McPhail","volume":"103","first-page":"1899","unstructured":null,"article-title":"Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements","journal-title":"Haematologica","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.19.00743","key":"2026011411214708100_bib15","year":"2019","issue":"35","author":"Rosenwald","volume":"37","first-page":"3359","unstructured":null,"article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2015-05-647602","key":"2026011411214708100_bib16","year":"2015","issue":"22","author":"Copie-Bergman","volume":"126","first-page":"2466","unstructured":null,"article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1111/ejh.12212","key":"2026011411214708100_bib17","year":"2014","issue":"1","author":"Pedersen","volume":"92","first-page":"42","unstructured":null,"article-title":"MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations","journal-title":"Eur J Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2014-05-578963","key":"2026011411214708100_bib18","year":"2014","issue":"15","author":"Petrich","volume":"124","first-page":"2354","unstructured":null,"article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2017.72.2157","key":"2026011411214708100_bib19","year":"2017","issue":"20","author":"Landsburg","volume":"35","first-page":"2260","unstructured":null,"article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjh.12982","key":"2026011411214708100_bib20","year":"2014","issue":"6","author":"Oki","volume":"166","first-page":"891","unstructured":null,"article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","journal-title":"Br J Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjh.13463","key":"2026011411214708100_bib21","year":"2015","issue":"4","author":"Howlett","volume":"170","first-page":"504","unstructured":null,"article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","journal-title":"Br J Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2352-3026(18)30177-7","key":"2026011411214708100_bib22","year":"2018","issue":"12","author":"Dunleavy","volume":"5","first-page":"e609","unstructured":null,"article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","journal-title":"Lancet Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.18.01994","key":"2026011411214708100_bib23","year":"2019","issue":"21","author":"Bartlett","volume":"37","first-page":"1790","unstructured":null,"article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.26068","key":"2026011411214708100_bib24","year":"2021","issue":"3","author":"Laude","volume":"96","first-page":"302","unstructured":null,"article-title":"First-line treatment of double-hit and triple-hit lymphomas: survival and tolerance data from a retrospective multicenter French study","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.3324/haematol.2022.281461","key":"2026011411214708100_bib25","year":"2023","issue":"4","author":"Goyal","volume":"108","first-page":"1190","unstructured":null,"article-title":"Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States","journal-title":"Haematologica","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024025603","key":"2026011411214708100_bib26","year":"2024","issue":"15","author":"Collinge","volume":"144","first-page":"1611","unstructured":null,"article-title":"Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2003-05-1545","key":"2026011411214708100_bib27","year":"2004","issue":"1","author":"Hans","volume":"103","first-page":"275","unstructured":null,"article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2011.41.0985","key":"2026011411214708100_bib28","year":"2012","issue":"28","author":"Johnson","volume":"30","first-page":"3452","unstructured":null,"article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2017-12-820605","key":"2026011411214708100_bib29","year":"2018","issue":"18","author":"Scott","volume":"131","first-page":"2060","unstructured":null,"article-title":"High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2020005846","key":"2026011411214708100_bib30","year":"2021","issue":"7","author":"Freeman","volume":"137","first-page":"929","unstructured":null,"article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clml.2014.12.015","key":"2026011411214708100_bib31","year":"2015","issue":"6","author":"Sun","volume":"15","first-page":"341","unstructured":null,"article-title":"Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with Rituximab followed by hematopoietic stem cell transplantation","journal-title":"Clin Lymphoma Myeloma Leuk","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2023010402","key":"2026011411214708100_bib32","year":"2023","issue":"24","author":"Urata","volume":"7","first-page":"7459","unstructured":null,"article-title":"Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.1016/0197-2456(96)00075-X","key":"2026011411214708100_bib33","year":"1996","issue":"4","author":"Schemper","volume":"17","first-page":"343","unstructured":null,"article-title":"A note on quantifying follow-up in studies of failure time","journal-title":"Control Clin Trials","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.V99.8.2685","key":"2026011411214708100_bib34","year":"2002","issue":"8","author":"Wilson","volume":"99","first-page":"2685","unstructured":null,"article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2019000875","key":"2026011411214708100_bib35","year":"2020","issue":"2","author":"Torka","volume":"4","first-page":"253","unstructured":null,"article-title":"Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2019000251","key":"2026011411214708100_bib36","year":"2019","issue":"13","author":"Barraclough","volume":"3","first-page":"2013","unstructured":null,"article-title":"COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.18632/oncotarget.9473","key":"2026011411214708100_bib37","year":"2016","issue":"25","author":"Li","volume":"7","first-page":"38122","unstructured":null,"article-title":"Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma","journal-title":"Oncotarget","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2012.48.3990","key":"2026011411214708100_bib38","year":"2013","issue":"26","author":"Link","volume":"31","first-page":"3272","unstructured":null,"article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic specialized program of research excellence molecular epidemiology resource","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjh.12570","key":"2026011411214708100_bib39","year":"2013","issue":"4","author":"Ban-Hoefen","volume":"163","first-page":"487","unstructured":null,"article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","journal-title":"Br J Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2019000258","key":"2026011411214708100_bib40","year":"2019","issue":"9","author":"Freeman","volume":"134","first-page":"761","unstructured":null,"article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2023020780","key":"2026011411214708100_bib41","year":"2024","issue":"25","author":"Davies","volume":"144","first-page":"2583","unstructured":null,"article-title":"The high-grade B-cell lymphomas: double hit and more","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.3324/haematol.2019.238162","key":"2026011411214708100_bib42","year":"2020","issue":"12","author":"Chamuleau","volume":"105","first-page":"2805","unstructured":null,"article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","journal-title":"Haematologica","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.23.00033","key":"2026011411214708100_bib43","year":"2023","issue":"15","author":"Davies","volume":"41","first-page":"2718","unstructured":null,"article-title":"Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2023-178623","key":"2026011411214708100_bib44","year":"2023","issue":"suppl 1","author":"Morschhauser","volume":"142","first-page":"3000","unstructured":null,"article-title":"Deciphering the clinical benefit of pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024025355","key":"2026011411214708100_bib45","year":"2025","issue":"21","author":"Tumuluru","volume":"145","first-page":"2460","unstructured":null,"article-title":"Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024026831","key":"2026011411214708100_bib46","year":"2025","issue":"23","author":"Samples","volume":"145","first-page":"2762","unstructured":null,"article-title":"Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"update-policy":"https://doi.org/10.1182/blood.2019cm0000","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Blood Advances"],"published-other":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,1,27]]},"reference-count":46,"published-online":null,"references-count":46,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1182/bloodadvances.2025017282","is_oa":true,"title":"Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with\n MYC\n /\n BCL2\n rearrangements, DLBCL morphology","updated":"2026-01-17T01:14:18+00:00","published_date":"2025-10-10","best_oa_location":{"url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025017282/2416058/bloodadvances.2025017282.pdf","pmh_id":null,"url_for_pdf":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025017282/2416058/bloodadvances.2025017282.pdf","url_for_landing_page":"https://doi.org/10.1182/bloodadvances.2025017282"}}},"created_at":"2026-01-19T09:31:36.873Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"condition","value":"Diffuse Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"condition","value":"High-Grade B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"warning","value":"Design is an era-based observational before–after comparison; causality is uncertain.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"warning","value":"Sample size is not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025017282","tag_type":"warning","value":"Subgroup gains (immunoglobulin MYC partner, dark‑zone signature) are noted without effect sizes; the 43% and 77% likely indicate subgroup prevalence, not outcomes.","value_numeric":null}],"summaries":{"what_studied":"A province-wide guideline (2015–2020) recommending DA‑EPOCH‑R for fit patients ≤75 years with de novo HGBCL‑DH‑BCL2 of DLBCL morphology was compared with a historic era (2005–2010) predominantly treated with standard chemoimmunotherapy. Outcomes included 2‑year overall survival; DLBCL, NOS served as a comparator, and transformed follicular lymphoma cases in the DA‑EPOCH‑R era were described.","key_result":"Two‑year overall survival improved in HGBCL‑DH‑BCL2 with DA‑EPOCH‑R vs the historic era (75% vs 47%, P=.008), while DLBCL, NOS was unchanged (78% vs 76%, P=.17). Within HGBCL‑DH‑BCL2, tumors with immunoglobulin MYC partner loci (43%) and those expressing a dark‑zone signature (77%) showed the most pronounced survival improvements; in transformed FL, chemoimmunotherapy‑naïve patients had outcomes comparable to de novo disease, whereas those previously treated for FL had poor outcomes.","limitations":"Era-based, nonrandomized comparison limits causal inference. Sample size and absolute subgroup effect sizes are not provided in the abstract.","practice_takeaway":"For fit patients ≤75 years with de novo HGBCL‑DH‑BCL2 of DLBCL morphology, DA‑EPOCH‑R is supported by improved 2‑year survival at a population level. Consider biology: benefit appeared greatest with immunoglobulin MYC partners and a dark‑zone signature; prior chemoimmunotherapy before FL transformation portended poor outcomes."}}],"initialOffset":15,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Chemoimmunotherapy"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Chemoimmunotherapy"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Chemoimmunotherapy"}}}]]

Papers